Abstract Library

#3277 Single-institution experience with 18F-DOPA and 68Ga-DOTA-TOC as a PET imaging tracer for peptide receptor radionuclide therapy in well-differentiated neuroendocrine neoplasms

Introduction: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor affinity with 68Ga-DOTA, is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). 18F-FDOPA tracer is also used in the diagnostic imaging of NENs, likely detecting additional lesions compared to 68Ga-DOTA.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Veenstra E, Noordzij W,

Keywords: neuroendocrine tumor, PET tracer, 18F-DOPA, 68Ga-DOTA-TOC, carbidopa, peptide receptor radionuclide therapy, PRRT,

#3103 Comparison of 18F-DOPA versus 68Ga-DOTA-TOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms

Introduction: 18F-DOPA and 68Ga-DOTA-TOC are two diagnostic PET tracers used in neuroendocrine neoplasms (NENs). As both tracers utilise different metabolic pathways, lesion detection results often show disparities, but comparative studies are lacking.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Veenstra E

Authors: Veenstra E, de Groot D, Brouwers A, Walenkamp A, Noordzij W,

Keywords: neuroendocrine tumor, PET, tracer, 18F-DOPA, 68GA-DOTA-TOC, tumor marker, carbidopa,

#1097 Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells

Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment in patients with neuroendocrine tumors (NET). However, variability in tumoral sst2 expression might lead to variability in response. Epidrugs could increase sst2 levels and improve response to somatostatin analogues (SSA).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Vitale G,

Keywords: NET, sst2, epidrug, signaling,

#976 Upregulation of Somatostatin Receptor Type 2 Expression in Neuroendocrine Tumors by Epigenetic Modulation

Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment of neuroendocrine tumors (NETs). However, epigenetic mechanisms might account for the high variability in sst2 expression and treatment response between patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Farrell W, Dogan F, Waaijers A,

Keywords: GEP-NET, sst2, epigenetics,

#780 Epigenetic Regulation of Endogenous Somatostatin Expression in Neuroendocrine Tumors

Introduction: Somatostatin (SST) can regulate hormone secretion and cell proliferation in neuroendocrine tumors (NETs). SST expression levels in NETs likely differ between patients. DNA methylation inhibits gene transcription and can be reversed by the demethylating drug 5-aza-2-deoxycytidine (AZA).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Dogan F, Waaijers A, Sprij-Mooij D,

Keywords: somatostatin, epigenetics,